Brainstorm Cell Therapeutics Inc. (BCLI) EPS Estimated At $-0.14

July 14, 2018 - By Rene Reddy

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Logo

Analysts expect Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) to report $-0.14 EPS on August, 13.They anticipate $0.08 EPS change or 133.33 % from last quarter’s $-0.06 EPS. After having $-0.12 EPS previously, Brainstorm Cell Therapeutics Inc.’s analysts see 16.67 % EPS growth. The stock increased 1.68% or $0.07 during the last trading session, reaching $4.23. About 24,851 shares traded. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has risen 14.11% since July 14, 2017 and is uptrending. It has outperformed by 1.54% the S&P500.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, and others. The company has market cap of $85.66 million. The firm holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. It currently has negative earnings. The Company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons.

More notable recent Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) news were published by: Seekingalpha.com which released: “BrainStorm granted Japanese Patent for Nurown” on July 05, 2018, also Benzinga.com with their article: “20 Stocks Moving In Tuesday’s Pre-Market Session” published on July 03, 2018, Seekingalpha.com published: “Welcome To Right To Try” on June 21, 2018. More interesting news about Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) were released by: Streetinsider.com and their article: “Brainstorm Cell Therapeutics (BCLI) to Host Conference Call to Announce Its “Right To Try” Policy” published on June 25, 2018 as well as Benzinga.com‘s news article titled: “5 Stocks Moving In Wednesday’s After-Hours Session” with publication date: June 27, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.